Products for Research Use Only
RegisterLogin

Onalespib

CAT: 0804-HY-14463-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14463-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Onalespib (AT13387) is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor. Onalespib inhibits the proliferation, survival and migration. Onalespib decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib shows antitumor activity. Onalespib has the potential for the research of non-small cell lung cancer (NSCLC) [1][2][3].
CAS Number
912999-49-6
Product Name Alternative
AT13387
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
HSP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/AT13387.html
Purity
99.92
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
OC1=CC(O)=C(C(C)C)C=C1C(N2CC(C=CC(CN3CCN(C)CC3)=C4)=C4C2)=O
Molecular Formula
C24H31N3O3
Molecular Weight
409.52
Precautions
H302, H312, H332
References & Citations
[1]Riess JW, et al. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC) : A California Cancer Consortium Phase I/II Trial (NCI 9878) . Clin Lung Cancer. 2021 Nov;22 (6) :541-548. |[2]Canella A, et al. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clin Cancer Res. 2017 Oct 15;23 (20) :6215-6226. |[3]Woodhead AJ, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl) -[5- (4-methylpiperazin-1-ylmethyl) -1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem. 2010 Aug 26;53 (16) :5956-69.|[4]Spiegelberg D, et al. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach. Sci Rep. 2020 Apr 3;10 (1) :5923.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HSP90

Alternative Products

CatalogName
T6284-01Onalespib
C07573-01Onalespib (AT13387)
T28236-01Onalespib lactate
MBS130965-01Onalespib? AT-13387
200317Onalespib free base
A11062-25Onalespib (AT13387) 25mg
A11062-500Onalespib (AT13387) 500mg
A11062-1Onalespib (AT13387) 1mg

Popular Products